Pub Date : 2024-02-08DOI: 10.3897/pharmacia.71.e115952
Dana Dadanbekova, K. Zhakipbekov, Almat T Kodasbayev, U. Datkhayev, G. Petrova, K. Tachkov
The aim of this study is to evaluate the cost-effectiveness of 2 different therapies of cardiomyopathy (CM) after COVID -19. The focus of the study is fixed dose combination (FDC) of sacubitril/valsartan and standard therapy in Kazakhstan. This is written from the point of view of the health insurance institution. Information for the age, gender, CM therapy, number of hospitalizations, COVID-19 infection, and past cardiovascular surgeries of 237 patients with incidents of CM which required a hospitalization after a COVID-19 infection was collected. Selected patients were divided into two groups: the cost of FDC and standard therapy and the annual cost of their therapy was calculated. The incremental cost-effectiveness ratio was calculated by dividing the cost of medication therapy by the number of hospitalizations between the two compared groups. Robustness of the results was tested with deterministic and probabilistic sensitivity analyses. The study was performed in City cardiology centre of Almaty in Kazakhstan during 2020–2022. Results show that FDC is more costly but more effective, leading to fewer hospitalizations. ICER accounts for €-2,743.08 per hospitalization saved in the group on FDC vs standard of therapy. Sacubitril/valsartan is cost-effective in ambulatory conditions in comparison with standard therapy of cardiomyopathy after COVID-19 leading to savings due to the decrease in the number of hospitalizations.
{"title":"Cost-effectiveness of cardiomyopathy ambulatory care with sacubitril/valsartan vs standard therapy after COVID-19 in Kazakhstan","authors":"Dana Dadanbekova, K. Zhakipbekov, Almat T Kodasbayev, U. Datkhayev, G. Petrova, K. Tachkov","doi":"10.3897/pharmacia.71.e115952","DOIUrl":"https://doi.org/10.3897/pharmacia.71.e115952","url":null,"abstract":"The aim of this study is to evaluate the cost-effectiveness of 2 different therapies of cardiomyopathy (CM) after COVID -19. The focus of the study is fixed dose combination (FDC) of sacubitril/valsartan and standard therapy in Kazakhstan. This is written from the point of view of the health insurance institution.\u0000 Information for the age, gender, CM therapy, number of hospitalizations, COVID-19 infection, and past cardiovascular surgeries of 237 patients with incidents of CM which required a hospitalization after a COVID-19 infection was collected. Selected patients were divided into two groups: the cost of FDC and standard therapy and the annual cost of their therapy was calculated. The incremental cost-effectiveness ratio was calculated by dividing the cost of medication therapy by the number of hospitalizations between the two compared groups. Robustness of the results was tested with deterministic and probabilistic sensitivity analyses. The study was performed in City cardiology centre of Almaty in Kazakhstan during 2020–2022.\u0000 Results show that FDC is more costly but more effective, leading to fewer hospitalizations. ICER accounts for €-2,743.08 per hospitalization saved in the group on FDC vs standard of therapy.\u0000 Sacubitril/valsartan is cost-effective in ambulatory conditions in comparison with standard therapy of cardiomyopathy after COVID-19 leading to savings due to the decrease in the number of hospitalizations.","PeriodicalId":508564,"journal":{"name":"Pharmacia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139791276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-08DOI: 10.3897/pharmacia.71.e115198
Mohammed Mahmood Mohammed, Hayder Adnan Fawzi
Aim: Evaluate the prevalence of depression among professional healthcare workers (PHCW) during the COVID-19 pandemic. Methods: A cross-sectional study was conducted during the fourth wave of COVID-19 infection in Iraq. A semi-structured questionnaire in English was used to obtain information about the study variables. Results: The study included 314 participants, with a mean age of 34.3 years, slightly higher male to female sex (55.1 to 44.9%), doctors represent (26.1%), pharmacist represent (26.4%) while 36.9% includes other PHCW (nurse, laboratory technician, doctor assistance, and paramedics). There was a high prevalence of depression in the current study (98.4%). There was no significant association between total HADS with sex, specialty, and duration of working in COVID-19 isolation wards. Meanwhile, age above 50 years appears to be associated with higher HADS scores compared to younger PHCW. Conclusion: Healthcare practitioners faced a heightened susceptibility to experiencing depression throughout the COVID-19 pandemic.
{"title":"Assessment of anxiety and depression among professional healthcare workers during the COVID-19 pandemic – observational cross-sectional study","authors":"Mohammed Mahmood Mohammed, Hayder Adnan Fawzi","doi":"10.3897/pharmacia.71.e115198","DOIUrl":"https://doi.org/10.3897/pharmacia.71.e115198","url":null,"abstract":"Aim: Evaluate the prevalence of depression among professional healthcare workers (PHCW) during the COVID-19 pandemic.\u0000 Methods: A cross-sectional study was conducted during the fourth wave of COVID-19 infection in Iraq. A semi-structured questionnaire in English was used to obtain information about the study variables.\u0000 Results: The study included 314 participants, with a mean age of 34.3 years, slightly higher male to female sex (55.1 to 44.9%), doctors represent (26.1%), pharmacist represent (26.4%) while 36.9% includes other PHCW (nurse, laboratory technician, doctor assistance, and paramedics). There was a high prevalence of depression in the current study (98.4%). There was no significant association between total HADS with sex, specialty, and duration of working in COVID-19 isolation wards. Meanwhile, age above 50 years appears to be associated with higher HADS scores compared to younger PHCW.\u0000 Conclusion: Healthcare practitioners faced a heightened susceptibility to experiencing depression throughout the COVID-19 pandemic.","PeriodicalId":508564,"journal":{"name":"Pharmacia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139792294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-08DOI: 10.3897/pharmacia.71.e115198
Mohammed Mahmood Mohammed, Hayder Adnan Fawzi
Aim: Evaluate the prevalence of depression among professional healthcare workers (PHCW) during the COVID-19 pandemic. Methods: A cross-sectional study was conducted during the fourth wave of COVID-19 infection in Iraq. A semi-structured questionnaire in English was used to obtain information about the study variables. Results: The study included 314 participants, with a mean age of 34.3 years, slightly higher male to female sex (55.1 to 44.9%), doctors represent (26.1%), pharmacist represent (26.4%) while 36.9% includes other PHCW (nurse, laboratory technician, doctor assistance, and paramedics). There was a high prevalence of depression in the current study (98.4%). There was no significant association between total HADS with sex, specialty, and duration of working in COVID-19 isolation wards. Meanwhile, age above 50 years appears to be associated with higher HADS scores compared to younger PHCW. Conclusion: Healthcare practitioners faced a heightened susceptibility to experiencing depression throughout the COVID-19 pandemic.
{"title":"Assessment of anxiety and depression among professional healthcare workers during the COVID-19 pandemic – observational cross-sectional study","authors":"Mohammed Mahmood Mohammed, Hayder Adnan Fawzi","doi":"10.3897/pharmacia.71.e115198","DOIUrl":"https://doi.org/10.3897/pharmacia.71.e115198","url":null,"abstract":"Aim: Evaluate the prevalence of depression among professional healthcare workers (PHCW) during the COVID-19 pandemic.\u0000 Methods: A cross-sectional study was conducted during the fourth wave of COVID-19 infection in Iraq. A semi-structured questionnaire in English was used to obtain information about the study variables.\u0000 Results: The study included 314 participants, with a mean age of 34.3 years, slightly higher male to female sex (55.1 to 44.9%), doctors represent (26.1%), pharmacist represent (26.4%) while 36.9% includes other PHCW (nurse, laboratory technician, doctor assistance, and paramedics). There was a high prevalence of depression in the current study (98.4%). There was no significant association between total HADS with sex, specialty, and duration of working in COVID-19 isolation wards. Meanwhile, age above 50 years appears to be associated with higher HADS scores compared to younger PHCW.\u0000 Conclusion: Healthcare practitioners faced a heightened susceptibility to experiencing depression throughout the COVID-19 pandemic.","PeriodicalId":508564,"journal":{"name":"Pharmacia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139852194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-08DOI: 10.3897/pharmacia.71.e115952
Dana Dadanbekova, K. Zhakipbekov, Almat T Kodasbayev, U. Datkhayev, G. Petrova, K. Tachkov
The aim of this study is to evaluate the cost-effectiveness of 2 different therapies of cardiomyopathy (CM) after COVID -19. The focus of the study is fixed dose combination (FDC) of sacubitril/valsartan and standard therapy in Kazakhstan. This is written from the point of view of the health insurance institution. Information for the age, gender, CM therapy, number of hospitalizations, COVID-19 infection, and past cardiovascular surgeries of 237 patients with incidents of CM which required a hospitalization after a COVID-19 infection was collected. Selected patients were divided into two groups: the cost of FDC and standard therapy and the annual cost of their therapy was calculated. The incremental cost-effectiveness ratio was calculated by dividing the cost of medication therapy by the number of hospitalizations between the two compared groups. Robustness of the results was tested with deterministic and probabilistic sensitivity analyses. The study was performed in City cardiology centre of Almaty in Kazakhstan during 2020–2022. Results show that FDC is more costly but more effective, leading to fewer hospitalizations. ICER accounts for €-2,743.08 per hospitalization saved in the group on FDC vs standard of therapy. Sacubitril/valsartan is cost-effective in ambulatory conditions in comparison with standard therapy of cardiomyopathy after COVID-19 leading to savings due to the decrease in the number of hospitalizations.
{"title":"Cost-effectiveness of cardiomyopathy ambulatory care with sacubitril/valsartan vs standard therapy after COVID-19 in Kazakhstan","authors":"Dana Dadanbekova, K. Zhakipbekov, Almat T Kodasbayev, U. Datkhayev, G. Petrova, K. Tachkov","doi":"10.3897/pharmacia.71.e115952","DOIUrl":"https://doi.org/10.3897/pharmacia.71.e115952","url":null,"abstract":"The aim of this study is to evaluate the cost-effectiveness of 2 different therapies of cardiomyopathy (CM) after COVID -19. The focus of the study is fixed dose combination (FDC) of sacubitril/valsartan and standard therapy in Kazakhstan. This is written from the point of view of the health insurance institution.\u0000 Information for the age, gender, CM therapy, number of hospitalizations, COVID-19 infection, and past cardiovascular surgeries of 237 patients with incidents of CM which required a hospitalization after a COVID-19 infection was collected. Selected patients were divided into two groups: the cost of FDC and standard therapy and the annual cost of their therapy was calculated. The incremental cost-effectiveness ratio was calculated by dividing the cost of medication therapy by the number of hospitalizations between the two compared groups. Robustness of the results was tested with deterministic and probabilistic sensitivity analyses. The study was performed in City cardiology centre of Almaty in Kazakhstan during 2020–2022.\u0000 Results show that FDC is more costly but more effective, leading to fewer hospitalizations. ICER accounts for €-2,743.08 per hospitalization saved in the group on FDC vs standard of therapy.\u0000 Sacubitril/valsartan is cost-effective in ambulatory conditions in comparison with standard therapy of cardiomyopathy after COVID-19 leading to savings due to the decrease in the number of hospitalizations.","PeriodicalId":508564,"journal":{"name":"Pharmacia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139851120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-05DOI: 10.3897/pharmacia.71.e114120
E. Mateev, Ali Irfan, Alexandrina Mateeva, M. Kondeva-Burdina, Maya Georgieva, A. Zlatkov
Virtual screening is emerging as a highly applied technique and gained prominence as widely used method for the search and identification of potential hits, significantly reducing the time needed to discover novel and effective compounds compared to high-throughput screening. Recently, the superiority of simulations with multiple programs compared to a single software docking has been discussed. The aim of this work was to apply consensus docking, molecular mechanics/generalized Born surface area (MM/GBSA) free binding energy recalculations, and in vitro evaluations on an in-house dataset of recently synthesized pyrrole-based hydrazide-hydrazones in the search for novel acetylcholinesterase (AChE) inhibitors. Two licensed softwares – GOLD 5.3 and Glide, were employed for the virtual screenings, and several chemotherapeutic potential hits were identified. Furthermore, MM/GBSA free binding energy recalculations were provided to enhance the robustness of the in silico results. The MM/GBSA scores of the top ten pyrrole-based hydrazide-hydrazones were ranging from -60.44 to -70.93 Kcal/mol. Subsequent, in vitro evaluations of the top ranked compounds revealed that 12d exhibited the highest AChE inhibitory activity, with a 55% inhibition rate at a concentration of 10 μM. Moreover, this prominent pyrrole-based AChE inhibitor formed stable complex with the active site of the enzyme. Interactions with the active amino residues Tyr72 and Tyr286 indicated that 12d was located near the peripheral anionic site of the enzyme. Additionally, in silicoADME investigations using QikProp demonstrated that 12d possesses optimal pharmacokinetic properties. In conclusion, this study identified a novel pyrrole-based AChE inhibitor 12d through a combination of computational and experimental findings.
{"title":"In silico and in vitro screening of pyrrole-based Hydrazide-Hydrazones as novel acetylcholinesterase inhibitors","authors":"E. Mateev, Ali Irfan, Alexandrina Mateeva, M. Kondeva-Burdina, Maya Georgieva, A. Zlatkov","doi":"10.3897/pharmacia.71.e114120","DOIUrl":"https://doi.org/10.3897/pharmacia.71.e114120","url":null,"abstract":"Virtual screening is emerging as a highly applied technique and gained prominence as widely used method for the search and identification of potential hits, significantly reducing the time needed to discover novel and effective compounds compared to high-throughput screening. Recently, the superiority of simulations with multiple programs compared to a single software docking has been discussed. The aim of this work was to apply consensus docking, molecular mechanics/generalized Born surface area (MM/GBSA) free binding energy recalculations, and in vitro evaluations on an in-house dataset of recently synthesized pyrrole-based hydrazide-hydrazones in the search for novel acetylcholinesterase (AChE) inhibitors. Two licensed softwares – GOLD 5.3 and Glide, were employed for the virtual screenings, and several chemotherapeutic potential hits were identified. Furthermore, MM/GBSA free binding energy recalculations were provided to enhance the robustness of the in silico results. The MM/GBSA scores of the top ten pyrrole-based hydrazide-hydrazones were ranging from -60.44 to -70.93 Kcal/mol. Subsequent, in vitro evaluations of the top ranked compounds revealed that 12d exhibited the highest AChE inhibitory activity, with a 55% inhibition rate at a concentration of 10 μM. Moreover, this prominent pyrrole-based AChE inhibitor formed stable complex with the active site of the enzyme. Interactions with the active amino residues Tyr72 and Tyr286 indicated that 12d was located near the peripheral anionic site of the enzyme. Additionally, in silicoADME investigations using QikProp demonstrated that 12d possesses optimal pharmacokinetic properties. In conclusion, this study identified a novel pyrrole-based AChE inhibitor 12d through a combination of computational and experimental findings.","PeriodicalId":508564,"journal":{"name":"Pharmacia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139803196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-05DOI: 10.3897/pharmacia.71.e114120
E. Mateev, Ali Irfan, Alexandrina Mateeva, M. Kondeva-Burdina, Maya Georgieva, A. Zlatkov
Virtual screening is emerging as a highly applied technique and gained prominence as widely used method for the search and identification of potential hits, significantly reducing the time needed to discover novel and effective compounds compared to high-throughput screening. Recently, the superiority of simulations with multiple programs compared to a single software docking has been discussed. The aim of this work was to apply consensus docking, molecular mechanics/generalized Born surface area (MM/GBSA) free binding energy recalculations, and in vitro evaluations on an in-house dataset of recently synthesized pyrrole-based hydrazide-hydrazones in the search for novel acetylcholinesterase (AChE) inhibitors. Two licensed softwares – GOLD 5.3 and Glide, were employed for the virtual screenings, and several chemotherapeutic potential hits were identified. Furthermore, MM/GBSA free binding energy recalculations were provided to enhance the robustness of the in silico results. The MM/GBSA scores of the top ten pyrrole-based hydrazide-hydrazones were ranging from -60.44 to -70.93 Kcal/mol. Subsequent, in vitro evaluations of the top ranked compounds revealed that 12d exhibited the highest AChE inhibitory activity, with a 55% inhibition rate at a concentration of 10 μM. Moreover, this prominent pyrrole-based AChE inhibitor formed stable complex with the active site of the enzyme. Interactions with the active amino residues Tyr72 and Tyr286 indicated that 12d was located near the peripheral anionic site of the enzyme. Additionally, in silicoADME investigations using QikProp demonstrated that 12d possesses optimal pharmacokinetic properties. In conclusion, this study identified a novel pyrrole-based AChE inhibitor 12d through a combination of computational and experimental findings.
{"title":"In silico and in vitro screening of pyrrole-based Hydrazide-Hydrazones as novel acetylcholinesterase inhibitors","authors":"E. Mateev, Ali Irfan, Alexandrina Mateeva, M. Kondeva-Burdina, Maya Georgieva, A. Zlatkov","doi":"10.3897/pharmacia.71.e114120","DOIUrl":"https://doi.org/10.3897/pharmacia.71.e114120","url":null,"abstract":"Virtual screening is emerging as a highly applied technique and gained prominence as widely used method for the search and identification of potential hits, significantly reducing the time needed to discover novel and effective compounds compared to high-throughput screening. Recently, the superiority of simulations with multiple programs compared to a single software docking has been discussed. The aim of this work was to apply consensus docking, molecular mechanics/generalized Born surface area (MM/GBSA) free binding energy recalculations, and in vitro evaluations on an in-house dataset of recently synthesized pyrrole-based hydrazide-hydrazones in the search for novel acetylcholinesterase (AChE) inhibitors. Two licensed softwares – GOLD 5.3 and Glide, were employed for the virtual screenings, and several chemotherapeutic potential hits were identified. Furthermore, MM/GBSA free binding energy recalculations were provided to enhance the robustness of the in silico results. The MM/GBSA scores of the top ten pyrrole-based hydrazide-hydrazones were ranging from -60.44 to -70.93 Kcal/mol. Subsequent, in vitro evaluations of the top ranked compounds revealed that 12d exhibited the highest AChE inhibitory activity, with a 55% inhibition rate at a concentration of 10 μM. Moreover, this prominent pyrrole-based AChE inhibitor formed stable complex with the active site of the enzyme. Interactions with the active amino residues Tyr72 and Tyr286 indicated that 12d was located near the peripheral anionic site of the enzyme. Additionally, in silicoADME investigations using QikProp demonstrated that 12d possesses optimal pharmacokinetic properties. In conclusion, this study identified a novel pyrrole-based AChE inhibitor 12d through a combination of computational and experimental findings.","PeriodicalId":508564,"journal":{"name":"Pharmacia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139863122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-02DOI: 10.3897/pharmacia.71.e112909
Ala Abu-Zaid, Sawsan Abu-Zaid, M. Barakat, Rashed Al-Huniti, Hamzeh Khair
Vestibular migraine (VM) has conventionally been treated through acute migraine-aborting therapeutic interventions and prevention to reduce migraines’ occurrence, length and intensity. There is growing attention to the development of non-pharmaceutical prophylactic interventions for migraines in the search for effective treatments, such as through mineral, vitamin and other supplementation. This research aims to examine the effectiveness of magnesium, vitamin B2 and Co-enzyme 10 supplementation to decrease vestibular migraines’ frequency, duration and severity. Method: This retrospective cohort study was conducted in a Jordanian context over 57- VM patients, each patient attending the outpatient dizziness clinic between August 2022 and February 2023. Patients were treated for six months with a combined supplementation of magnesium, vitamin B2, and Co-enzyme Q10. Assessments were made of three measures of VM attack, namely frequency, duration and severity, both before and after intervention. Result: Supplements administration demonstrated a significant reduction (by 81.1%) in VM-symptoms frequency (p < 0.001). Moreover, reductions in symptom duration in minutes occurred progressively as the treatment period continued and showed statistical significance, with impacts upon over 80% of the sample and a reduction from 763.9 minutes to 122.5 minutes (p < 0.001). The mean of pre-intervention severity was 7.2/10, with a significant decrease shown following treatment, at 2.1/10, and very positive results for over 71% of the sample (p < 0.001). Conclusion: The preliminary findings of this study showed a promising potential for such supplements in the treatment and prevention of VM; however, more research and a prospective trial are recommended.
{"title":"Effectiveness of combination therapy of magnesium, vitamin B2 and Co-enzyme 10 supplementation on vestibular migraine: a retrospective cohort study","authors":"Ala Abu-Zaid, Sawsan Abu-Zaid, M. Barakat, Rashed Al-Huniti, Hamzeh Khair","doi":"10.3897/pharmacia.71.e112909","DOIUrl":"https://doi.org/10.3897/pharmacia.71.e112909","url":null,"abstract":"Vestibular migraine (VM) has conventionally been treated through acute migraine-aborting therapeutic interventions and prevention to reduce migraines’ occurrence, length and intensity. There is growing attention to the development of non-pharmaceutical prophylactic interventions for migraines in the search for effective treatments, such as through mineral, vitamin and other supplementation. This research aims to examine the effectiveness of magnesium, vitamin B2 and Co-enzyme 10 supplementation to decrease vestibular migraines’ frequency, duration and severity. Method: This retrospective cohort study was conducted in a Jordanian context over 57- VM patients, each patient attending the outpatient dizziness clinic between August 2022 and February 2023. Patients were treated for six months with a combined supplementation of magnesium, vitamin B2, and Co-enzyme Q10. Assessments were made of three measures of VM attack, namely frequency, duration and severity, both before and after intervention. Result: Supplements administration demonstrated a significant reduction (by 81.1%) in VM-symptoms frequency (p < 0.001). Moreover, reductions in symptom duration in minutes occurred progressively as the treatment period continued and showed statistical significance, with impacts upon over 80% of the sample and a reduction from 763.9 minutes to 122.5 minutes (p < 0.001). The mean of pre-intervention severity was 7.2/10, with a significant decrease shown following treatment, at 2.1/10, and very positive results for over 71% of the sample (p < 0.001). Conclusion: The preliminary findings of this study showed a promising potential for such supplements in the treatment and prevention of VM; however, more research and a prospective trial are recommended.","PeriodicalId":508564,"journal":{"name":"Pharmacia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139869504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-02DOI: 10.3897/pharmacia.71.e112909
Ala Abu-Zaid, Sawsan Abu-Zaid, M. Barakat, Rashed Al-Huniti, Hamzeh Khair
Vestibular migraine (VM) has conventionally been treated through acute migraine-aborting therapeutic interventions and prevention to reduce migraines’ occurrence, length and intensity. There is growing attention to the development of non-pharmaceutical prophylactic interventions for migraines in the search for effective treatments, such as through mineral, vitamin and other supplementation. This research aims to examine the effectiveness of magnesium, vitamin B2 and Co-enzyme 10 supplementation to decrease vestibular migraines’ frequency, duration and severity. Method: This retrospective cohort study was conducted in a Jordanian context over 57- VM patients, each patient attending the outpatient dizziness clinic between August 2022 and February 2023. Patients were treated for six months with a combined supplementation of magnesium, vitamin B2, and Co-enzyme Q10. Assessments were made of three measures of VM attack, namely frequency, duration and severity, both before and after intervention. Result: Supplements administration demonstrated a significant reduction (by 81.1%) in VM-symptoms frequency (p < 0.001). Moreover, reductions in symptom duration in minutes occurred progressively as the treatment period continued and showed statistical significance, with impacts upon over 80% of the sample and a reduction from 763.9 minutes to 122.5 minutes (p < 0.001). The mean of pre-intervention severity was 7.2/10, with a significant decrease shown following treatment, at 2.1/10, and very positive results for over 71% of the sample (p < 0.001). Conclusion: The preliminary findings of this study showed a promising potential for such supplements in the treatment and prevention of VM; however, more research and a prospective trial are recommended.
{"title":"Effectiveness of combination therapy of magnesium, vitamin B2 and Co-enzyme 10 supplementation on vestibular migraine: a retrospective cohort study","authors":"Ala Abu-Zaid, Sawsan Abu-Zaid, M. Barakat, Rashed Al-Huniti, Hamzeh Khair","doi":"10.3897/pharmacia.71.e112909","DOIUrl":"https://doi.org/10.3897/pharmacia.71.e112909","url":null,"abstract":"Vestibular migraine (VM) has conventionally been treated through acute migraine-aborting therapeutic interventions and prevention to reduce migraines’ occurrence, length and intensity. There is growing attention to the development of non-pharmaceutical prophylactic interventions for migraines in the search for effective treatments, such as through mineral, vitamin and other supplementation. This research aims to examine the effectiveness of magnesium, vitamin B2 and Co-enzyme 10 supplementation to decrease vestibular migraines’ frequency, duration and severity. Method: This retrospective cohort study was conducted in a Jordanian context over 57- VM patients, each patient attending the outpatient dizziness clinic between August 2022 and February 2023. Patients were treated for six months with a combined supplementation of magnesium, vitamin B2, and Co-enzyme Q10. Assessments were made of three measures of VM attack, namely frequency, duration and severity, both before and after intervention. Result: Supplements administration demonstrated a significant reduction (by 81.1%) in VM-symptoms frequency (p < 0.001). Moreover, reductions in symptom duration in minutes occurred progressively as the treatment period continued and showed statistical significance, with impacts upon over 80% of the sample and a reduction from 763.9 minutes to 122.5 minutes (p < 0.001). The mean of pre-intervention severity was 7.2/10, with a significant decrease shown following treatment, at 2.1/10, and very positive results for over 71% of the sample (p < 0.001). Conclusion: The preliminary findings of this study showed a promising potential for such supplements in the treatment and prevention of VM; however, more research and a prospective trial are recommended.","PeriodicalId":508564,"journal":{"name":"Pharmacia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139809396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-30DOI: 10.3897/pharmacia.71.e116927
Ali H. Salama
This study evaluates ChatGPT, an AI-based language model, in addressing common pharmacist inquiries in community pharmacies. The assessment encompasses Drug-Drug Interactions, Adverse Drug Effects, Drug Dosage, and Alternative Therapies, each comprising 20 questions, totaling 80 questions. Responses from ChatGPT were compared against standard answers, generating textual and chart scores. Textual score was computed by relating correct answers to the total questions within each category, while chart score involved the total correct answers multiplied by the chart-type questions. ChatGPT exhibited distinct performance rates: 30% for Drug-Drug Interactions, 65% for Adverse Drug Effects, 35% for Drug Dosage, and an impressive 85% for Alternative Therapies. While Alternative Therapies displayed high accuracy, challenges arose in accurately addressing Drug Dosage and Drug-Drug Interactions. Conclusion: The study underscores the complexity of pharmacy-related inquiries and the necessity for AI model enhancement. Despite promising accuracy in certain categories, like Alternative Therapies, improvements are crucial for Drug Dosage and Drug-Drug Interactions. The findings emphasize the need for ongoing AI model development to optimize integration into community pharmacy settings.
{"title":"The promise and challenges of ChatGPT in community pharmacy: A comparative analysis of response accuracy","authors":"Ali H. Salama","doi":"10.3897/pharmacia.71.e116927","DOIUrl":"https://doi.org/10.3897/pharmacia.71.e116927","url":null,"abstract":"This study evaluates ChatGPT, an AI-based language model, in addressing common pharmacist inquiries in community pharmacies. The assessment encompasses Drug-Drug Interactions, Adverse Drug Effects, Drug Dosage, and Alternative Therapies, each comprising 20 questions, totaling 80 questions. Responses from ChatGPT were compared against standard answers, generating textual and chart scores. Textual score was computed by relating correct answers to the total questions within each category, while chart score involved the total correct answers multiplied by the chart-type questions. ChatGPT exhibited distinct performance rates: 30% for Drug-Drug Interactions, 65% for Adverse Drug Effects, 35% for Drug Dosage, and an impressive 85% for Alternative Therapies. While Alternative Therapies displayed high accuracy, challenges arose in accurately addressing Drug Dosage and Drug-Drug Interactions. Conclusion: The study underscores the complexity of pharmacy-related inquiries and the necessity for AI model enhancement. Despite promising accuracy in certain categories, like Alternative Therapies, improvements are crucial for Drug Dosage and Drug-Drug Interactions. The findings emphasize the need for ongoing AI model development to optimize integration into community pharmacy settings.","PeriodicalId":508564,"journal":{"name":"Pharmacia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140483981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-30DOI: 10.3897/pharmacia.71.e115330
Taif Abdullah, Khalid Al-Kinani
A lack of safe and effective topical alternatives to oral propranolol HCl (PHCl) hampers optimal management of infantile hemangioma (IH), particularly in complex cases with severe side effects or treatment failures. This study aimed to develop a nanoemulsion gel (NEG) for topical PHCl delivery. A meticulously formulated nanoemulsion (NE) encapsulated with clove oil, Tween 20, and polyethylene glycol 400 emerged as the standout candidate (NE3) due to its exceptional stability, resilience, and favorable drug loading. NE3 exhibited a remarkable globule size of 14.57 nm, a low polydispersity index (PDI) of 0.282, and a stabilizing zeta potential of −19.89 mV. The subsequent formulation of PHCl-NEG displayed desired rheological and spreadability properties for topical application. Ex-vivo skin retention and permeation studies revealed effective PHCl deposition within the dermal layer with minimal systemic exposure. This promising approach offers a potential alternative to oral PHCl, potentially mitigating severe side effects and improving outcomes in complex IH cases.
{"title":"Propranolol nanoemulgel: Preparation, in-vitro and ex-vivo characterization for a potential local hemangioma therapy","authors":"Taif Abdullah, Khalid Al-Kinani","doi":"10.3897/pharmacia.71.e115330","DOIUrl":"https://doi.org/10.3897/pharmacia.71.e115330","url":null,"abstract":"A lack of safe and effective topical alternatives to oral propranolol HCl (PHCl) hampers optimal management of infantile hemangioma (IH), particularly in complex cases with severe side effects or treatment failures. This study aimed to develop a nanoemulsion gel (NEG) for topical PHCl delivery. A meticulously formulated nanoemulsion (NE) encapsulated with clove oil, Tween 20, and polyethylene glycol 400 emerged as the standout candidate (NE3) due to its exceptional stability, resilience, and favorable drug loading. NE3 exhibited a remarkable globule size of 14.57 nm, a low polydispersity index (PDI) of 0.282, and a stabilizing zeta potential of −19.89 mV. The subsequent formulation of PHCl-NEG displayed desired rheological and spreadability properties for topical application. Ex-vivo skin retention and permeation studies revealed effective PHCl deposition within the dermal layer with minimal systemic exposure. This promising approach offers a potential alternative to oral PHCl, potentially mitigating severe side effects and improving outcomes in complex IH cases.","PeriodicalId":508564,"journal":{"name":"Pharmacia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140481542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：